Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Odanacatib Filing Pushed Back, Merck Reports Flat Top-Line Growth In 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s delay of filing an NDA for its osteoporosis drug odanacatib surprised analysts, but Merck remained mum on its reasoning in a year-end earnings call on Feb. 1.


Related Content

Merck Moves Forward With Odanacatib Filing; FDA Accepts MK-3475 Filing
Emerging Markets Earnings Roundup: Merck And Novo Nordisk (Part 5)
Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE
Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts